Hotgen Biotech: Subsidiary innovative drug SGT003 injection liquid received drug clinical trial approval notice.

HotGen Bio announced that the clinical trial application for the innovative drug SGT003 injection developed by its subsidiary, Beijing Shunjing Biomedical Technology Co., Ltd., has been approved by the National Medical Products Administration. SGT003 injection is the world's first novel dual-specificity antibody candidate drug to enter clinical research developed based on Shunjing Pharmaceutical's independently constructed NexTreg technology platform. Its core innovation lies in precisely eliminating tumor microenvironment regulatory T cells, activating anti-tumor immunity.